Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 37, Issue 5, pp 499–501 | Cite as

Plasma alcohol concentrations in patients following paclitaxel infusion

  • Lorraine K. Webster
  • Nicholas A. Crinis
  • Carmel G. Morton
  • Michael J. Millward
Short communication

Abstract

Paclitaxel is formulated in 50% Cremophor EL and 50% ethanol such that patients receiving paclitaxel also receive a significant amount of each of these solvents. The aim of this study was to measure the plasma alcohol levels in patients treated with paclitaxel. A total of 12 patients who were enrolled in phase II trials of non-small-cell lung cancer, breast cancer or ovarian cancer received 175 mg/m2 paclitaxel given as a 3-h infusion. Blood samples were obtained prior to and immediately following the infusion, and plasma ethanol concentrations were measured enzymatically. The dose of ethanol delivered with the paclitaxel ranged from 20.0 to 28.9 ml. No alcohol was detected in pre-dose plasma, but 8 of 12 patients had detectable levels in post-infusion plasma, with 0.033 g/dl being the highest concentration. The elimination rate of alcohol approximates the infusion rate when paclitaxel is given over 3 h, resulting in low or undetectable levels in most patients. However, in patients receiving an equivalent dose of paclitaxel given as a 1-h infusion, the plasma alcohol levels will likely be high nough for significant pharmacological effects to occur.

Key words

Paclitaxel Drug interaction Ethanol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Eisenhauer EA, Bokkel Huinink WW ten, Swenerton KD, Gianni L, Myles J, Burg MEL van der, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetta R (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654PubMedGoogle Scholar
  2. 2.
    Hainsworth JD, Greco FA (1994) Paclitaxel administered by 1-hour infusion: preliminary results of a phase I/II trial comparing two schedules. Cancer 74:1377PubMedCrossRefGoogle Scholar
  3. 3.
    Meier-Tackmann D, Leonhardt RA, Agarwal DP, Werner Goedde H (1990) Effect of acute ethanol drinking on alcohol metabolism in subjects with different ADH and ALDH genotypes. Alcohol 7:413PubMedCrossRefGoogle Scholar
  4. 4.
    Rall TW (1990) Hypnotics and sedatives; ethanol. In: Goodman AG, et al (eds). The pharmacological basis of therapeutics, 8th edn. Pergamon Press, New York, pp 370–380Google Scholar
  5. 5.
    Rowinsky EK, Onetto N, Canetta RM, Arbuck SG (1992) Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 19:6463.Google Scholar
  6. 6.
    Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D (1994) Phase I trial of a 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12:241PubMedGoogle Scholar
  7. 7.
    Smith GD, Shaw LJ, Maini PK, Ward RJ, Peters TJ, Murray JD (1993) Mathematical modelling of ethanol metabolism in normal subjects and chronic alcohol misusers. Alcohol Alcohol 28:25PubMedGoogle Scholar
  8. 8.
    Webster LK, Linsenmeyer M, Millward MJ, Morton CG, Bishop JF, Woodcock DM (1993) Measurement of Cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug resistance phenotype. J Natl Cancer Inst 85:1685PubMedCrossRefGoogle Scholar
  9. 9.
    Yamanaka-Yuen NA (1993) Principles of ethanol drug interactions. In: Hansten PD, Horn JR (eds) Drug interactions and updates, vol 13. Applied Therapeutics Inc., Vancouver, Washington, p 90Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • Lorraine K. Webster
    • 1
  • Nicholas A. Crinis
    • 2
  • Carmel G. Morton
    • 3
  • Michael J. Millward
    • 3
  1. 1.Division of ResearchPeter MacCallum Cancer InstituteMelbourneAustralia
  2. 2.Department of PathologyPeter MacCallum Cancer InstituteMelbourneAustralia
  3. 3.Division of Haematology and Medical OncologyPeter MacCallum Cancer InstituteAustralia

Personalised recommendations